CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs
Policy / Regulatory

CDE Opens Public Comment on 111th Batch Draft of Reference Preparations Catalogue – 25 New Specifications Proposed for Chemical Generic Drugs

China's Center for Drug Evaluation (CDE) has released the draft for comment of the 111st Batch of the Catalogue of Reference Preparations for Chemical Generic Drugs, proposing 25 newly added…

BioMarin's Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World's Largest Rare Bone Disease Market
CompanyDrug

BioMarin’s Vosoritide Wins NMPA Approval in China – First CNP-Analog Therapy for Pediatric Achondroplasia Enters the World’s Largest Rare Bone Disease Market

FDA Approves AbbVie's Tavapadon as Juvmo for Parkinson's Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfoli
CompanyDrug

FDA Approves AbbVie’s Tavapadon as Juvmo for Parkinson’s Disease – Once‑Daily Dopamine Mimetic Joins $8.7 Billion Cerevel Portfolio

Jenscare's JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market
CompanyMedical Device

Jenscare’s JensClip Wins NMPA Registration Approval – Self‑Locking Transcatheter Mitral Valve Repair Clip Enters the Chinese Market

Merck's Subcutaneous Pembrolizumab Approved by China's NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China
CompanyDrug

Merck’s Subcutaneous Pembrolizumab Approved by China’s NMPA Across 19 Solid Tumor Indications – First and Only Subcutaneous PD‑1 Inhibitor in China

FDA Approves Priovant's LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication
CompanyDrug

FDA Approves Priovant’s LISRAYA (Brepocitinib) for Adult Dermatomyositis – First Oral Targeted JAK1/TYK2 Therapy in the Indication

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
CompanyDrug

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors
CompanyDrug

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer
CompanyDrug

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

CSPC Innovation Pharmaceutical's ADC Candidate SYS6062 Wins NMPA Clinical Trial Approval – Advances in Advanced Solid Tumors
CompanyDrug

CSPC Innovation Pharmaceutical’s ADC Candidate SYS6062 Wins NMPA Clinical Trial Approval – Advances in Advanced Solid Tumors

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million

MicuRx Pharmaceuticals Licenses MRX‑23 ADC and STOPIN Platform to ClearideBio in Multi‑Asset Global Deal Worth Up to USD 973 Million

Shanghai MicuRx Pharmaceuticals, Inc. (SHA: 688373) announced that it intends to enter into an MRX‑23 License Agreement and a Platform Technology Cooperation Agreement with ClearideBio Therapeutics AG, a Switzerland‑based biopharmaceutical company. The dual‑track transaction grants ClearideBio exclusive global rights to…

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Defand Therapeutics Enters Research Collaboration with Roche – Novel Molecular Glue Degrader Platform Targets Oncology and Immunology

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases
CompanyR&D

Brii Biosciences Launches BRiSC Bispecific siRNA Platform – Dual‑Target RNAi Engine to Advance Next‑Generation RNA Therapeutics in Prevalent Diseases

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035
CompanyDeals

Adlai Nortye Strikes Cetuximab Supply Deals with Eli Lilly and Merck KGaA – Backing Global Phase 1 Trial of First‑in‑Class CEACAM5 ADC AN4035

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection
CompanyDeals

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

FDA Clears Legend Biotech's IND for LB2501 – Off‑the‑Shelf In Vivo CD19/CD20 CAR‑T Enters U.S. Phase I/II Without Lymphodepleting Chemotherapy
CompanyDrug

FDA Clears Legend Biotech’s IND for LB2501 – Off‑the‑Shelf In Vivo CD19/CD20 CAR‑T Enters U.S. Phase I/II Without Lymphodepleting Chemotherapy

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies
CompanyDeals

insitro Signs Worldwide Exclusive Research Deal with AstraZeneca – Up to USD 1.5 Billion to Apply Virtual Human Platform in MASH and Cardiomyopathies

Where biopharma's biggest deals take shape!

Your front-row seat to the deals reshaping the pharmaceutical landscape — mergers and acquisitions, licensing agreements, venture investments, and strategic partnerships. We track every major transaction, from blockbuster M&As to early-stage funding rounds, breaking down what each deal means for the companies, the pipeline, and the market.
M&A and Licensing
ChemPartner and BioBAY Open Arsenal Innovation Center in Massachusetts – Bridging Suzhou and Boston Life Science Ecosystems
CompanyDeals

ChemPartner and BioBAY Open Arsenal Innovation Center in Massachusetts – Bridging Suzhou and Boston Life Science Ecosystems

ChemPartner Pharmatech Co., Ltd (SHE: 300149) announced that the Arsenal Innovation Center, established in collaboration with BioBAY – the Suzhou‑based life sciences innovation park – has officially opened in Watertown,…

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones
CompanyDeals

Vir Biotechnology and Gilead Strike Collaboration to Engineer Three PRO‑XTEN Dual‑Masked T‑Cell Engagers – Deal Worth Up to USD 1.88 Billion in Milestones

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties
CompanyDeals

Yatai Pharma Subsidiary Shengyao Guangyan Signs LOI to Acquire BODIPY‑Type Photosensitizer for Acne – Class 1.1 Photodynamic Asset with Up to RMB 65 Million in Milestones Plus Royalties

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy
CompanyDeals

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery
CompanyDeals

Roche Inks Exclusive Worldwide License With Rona Therapeutics for ALK7‑Targeting RNAi Candidate – Up to USD 1.16 Billion Deal Advances Genetically Validated Obesity Target via Extrahepatic Delivery

- Advertisement -
Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1
CompanyDeals

Allygen Biologics Closes Over RMB 300 Million Series A Led by Sherpa Healthcare Partners – Funding to Propel STAR‑BiADC Candidate ALG01 into Phase 1

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech's CNS and Brain‑Penetrant Drug Pipeline
CompanyDeals

Hyperway Pharmaceutical Closes Series B+ Financing Round – Penglai Private Fund and Hengdian Capital Back the Chengdu Biotech’s CNS and Brain‑Penetrant Drug Pipeline

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances "Closed‑Loop Nerve Bundle Modulation" Platform
CompanyDeals

Neurorevix Completes Tens of Millions RMB Angel Round Led by HSG – BCI and Neuromodulation Pioneer Advances “Closed‑Loop Nerve Bundle Modulation” Platform

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom
CompanyDeals

Tangzhi Pharma Secures Nearly RMB 100 Million Exclusive Financing from Fengnian Capital – Glyco Raw‑Material Platform Targets ADC and Nucleic‑Acid Drug Boom

MIIT and Nine Departments Issue China's "15th Five‑Year Plan for Pharmaceutical Industry Development" – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030
Policy / Regulatory

MIIT and Nine Departments Issue China’s “15th Five‑Year Plan for Pharmaceutical Industry Development” – Innovative Drug Sector Targeted to Grow Over 20 % Annually Through 2030

The Ministry of Industry and Information Technology (MIIT), together with nine other departments, formulated and issued the "15th Five‑Year Plan for Pharmaceutical Industry Development" (the "Plan"), setting quantitative industry targets…

NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030
Policy / Regulatory

NHC and NDRC Launch Expansion and Quality Enhancement Plan for Rehabilitation and Nursing Care – 0.48 Beds per 1,000 Population Targeted by 2030

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease
Policy / Regulatory

Five Innovative Therapies Enter the Rare Disease R&D Pilot Initiative – Spanning Blau Syndrome, Angelman Syndrome, ALS and Charcot‑Marie‑Tooth Disease

China's CDE Launches "Pioneer Plan" Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing
Policy / Regulatory

China’s CDE Launches “Pioneer Plan” Pilot to Advance New Approach Methodologies (NAMs) in Non‑Clinical Drug Evaluation – Aiming to Reduce, Refine, and Replace Animal Testing

More News

Walvax Initiates Phase I Trial of Lyophilized Shingles mRNA Vaccine – First‑in‑Class Herpes Zoster Candidate Co‑Developed with Fudan University and RQ Biotech
CompanyDrug

Walvax Initiates Phase I Trial of Lyophilized Shingles mRNA Vaccine – First‑in‑Class Herpes Zoster Candidate Co‑Developed with Fudan University and RQ Biotech

Keymed Biosciences' Stapokibart Wins Fourth NMPA Indication – Adolescent Atopic Dermatitis Approval as Kangyueda Revenue Surges 227%
CompanyDrug

Keymed Biosciences’ Stapokibart Wins Fourth NMPA Indication – Adolescent Atopic Dermatitis Approval as Kangyueda Revenue Surges 227%

Novo Nordisk's NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China
CompanyDrug

Novo Nordisk’s NovoGlic Wins Expanded NMPA Approval – First Weekly Insulin Icodec/Semaglutide Combination Broadens Type 2 Diabetes Care in China

ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch
CompanyDrug

ArkBio Publishes Pivotal Phase 3 Data for Azstarys in Chinese Children with ADHD – NMPA‑Approved Dual‑Release Formulation Nears Commercial Launch

GenFleet's Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World's First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer
CompanyDrug

GenFleet’s Oral KRAS G12D Inhibitor GFH375/VS‑7375 Delivers Positive Data Across Global Studies – World’s First KRAS G12D Agent in Phase III for NSCLC and Pancreatic Cancer

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant
CompanyDrug

Centergate Technologies Subsidiary Duoduo Pharmaceutical Has Calcium Dobesilate Capsules Application Accepted by NMPA – Generic Filing Enters Review for Established Capillary Protectant

Tasly Pharmaceutical Receives NMPA Clinical Trial Approval for TDX105 Granules – Category 1.1 TCM Innovative Drug Targeting Chemotherapy‑Induced Hand‑Foot Skin Reactions
CompanyDrug

Tasly Pharmaceutical Receives NMPA Clinical Trial Approval for TDX105 Granules – Category 1.1 TCM Innovative Drug Targeting Chemotherapy‑Induced Hand‑Foot Skin Reactions

Sino Biopharmaceutical's Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation
CompanyDrug

Sino Biopharmaceutical’s Hepatitis B Assets Take Center Stage at AASLD 2026 – Bepirovirsen Phase 3 Functional Cure Data and TQ‑A3334 Late‑Breaking Phase II Results Slated for Oral Presentation

Show More